For a hepatocellular carcinoma patient beyond curative criteria (outside Milan criteria, vascular invasion, or not amenable to ablation) with preserved liver function (MELD‑Na <20, Child‑Pugh A‑B) and no contraindications, what immunotherapy regimen and additional locoregional or systemic interventions are recommended, and how should therapy be coordinated with liver transplantation planning?

Immunotherapy and Additional Interventions for Advanced HCC

For hepatocellular carcinoma beyond curative criteria with preserved liver function (Child-Pugh A), you should offer combination immunotherapy with a PD-1/PD-L1 inhibitor—specifically atezolizumab plus bevacizumab—as first-line systemic therapy, and reserve locoregional therapies (TACE/TAE) for liver-confined disease when a selective approach is technically feasible based on tumor size, number, and portal flow preservation 1.

First-Line Systemic Therapy Selection

The 2025 EASL guidelines provide the clearest directive: combinations including at least one PD-1 or PD-L1 inhibitor should be offered to patients with advanced HCC, Child-Pugh A liver function, and ECOG performance status 0-1, provided no contraindications exist 1. This represents a Level 1 evidence, strong recommendation with 100% consensus.

Atezolizumab plus bevacizumab is the preferred first-line regimen based on:

• Superior objective response rates (20-36%) compared to tyrosine kinase inhibitors in phase III trials 2
• Demonstrated efficacy even in patients with macrovascular invasion, showing median PFS of 6.0 months versus 4.1 months with locoregional therapy 3
• Comparable safety profile to locoregional approaches (11% major adverse events in both groups) 3

The choice should not be influenced by HCC etiology 1.

Coordinating Locoregional and Systemic Therapy

When to Prioritize Locoregional Therapy Over Immunotherapy

TACE/TAE should be preferred to systemic therapy for liver-confined disease when:

• Tumor size and number are low
• No infiltrative gross appearance is present
• Portal flow is preserved
• A selective approach is technically possible 1

This represents a strong recommendation despite Level 4 evidence, reflecting clinical consensus that anatomically favorable disease benefits from targeted embolization.

Combination Approaches: Current Limitations

Do not combine intra-arterial therapy (TACE/TAE or SIRT) with tyrosine kinase inhibitors in intermediate-stage patients with large tumor burden 1. This is a strong recommendation based on Level 2 evidence showing no benefit and potential harm.

For immunotherapy combinations with locoregional therapy, insufficient evidence exists for routine recommendation 1, though emerging data suggest potential synergy:

• Carbon-ion radiotherapy followed by immunotherapy showed high response rates (14/20 patients achieving CR/PR) in patients with low tumor burden and preserved liver function 4
• The combination appears most effective when tumor burden meets up-to-7 criteria and modified albumin-bilirubin grade is 1/2a 4

Special Considerations for Vascular Invasion

For patients with segmental or lobar portal vein invasion but no extrahepatic spread:

• Systemic therapy with immune checkpoint-based combinations remains the standard 1
• External beam radiotherapy (EBRT) cannot currently be recommended as an alternative to immunotherapy (Level 3 evidence, weak recommendation) 1
• SIRT is not recommended as an alternative to systemic therapy (Level 3 evidence, strong recommendation) 1

Recent real-world data support this approach: atezolizumab-bevacizumab achieved longer PFS than locoregional therapy in macrovascular invasion (HR 0.64, p<0.001) with comparable overall survival 3.

Liver Transplantation Planning and Downstaging

Immunotherapy-Based Downstaging: Emerging but Non-Standard

Immunotherapy for downstaging to transplant criteria should be restricted to carefully selected patients within multidisciplinary protocols, as this remains investigational 2. Key considerations:

Promising early data:

• ImmunoXXL trial: 16/16 patients successfully downstaged with atezolizumab-bevacizumab, achieving 62.5% complete pathological responses, 2-year recurrence-free survival of 90%, and overall survival of 94% 2
• VITALITY study: 75.6% successful downstaging beyond Milan criteria, with 36.7% proceeding to transplantation and 3-year post-transplant survival of 85% 2

Critical risk: acute allograft rejection occurs in 16-28% of transplanted patients with prior immune checkpoint inhibitor exposure 2. This represents a clinically significant complication that must be weighed against potential benefits.

Practical Framework for Transplant Candidates

If considering immunotherapy in a potential transplant candidate:

1. Restrict to patients with solitary intrahepatic tumors or oligolesional disease 4—these show highest conversion rates to clinical complete response
2. Ensure low tumor burden (within up-to-7 criteria) and preserved liver function (mALBI grade 1/2a) 4
3. Plan washout intervals before transplantation, though optimal duration remains undefined 2
4. Coordinate within multidisciplinary protocols with transplant hepatology involvement from treatment initiation 2, 5

For patients with recurrent HCC following transplantation: sorafenib or lenvatinib can be considered, but immune checkpoint inhibitors are not recommended due to organ rejection risk 1.

Child-Pugh B Patients: Selective Use

Patients with decompensated cirrhosis should not routinely receive systemic therapy outside clinical trials 1. However, systemic therapy may be considered in carefully selected patients with mild impairment (Child-Pugh 7-8) 1.

Recent data suggest atezolizumab-bevacizumab may prolong PFS in Child-Pugh B patients compared to tyrosine kinase inhibitors 6. For Child-Pugh score of 7, an mALBI grade of 3 independently predicts worse overall survival 6, helping identify patients unlikely to benefit.

Sequencing and Subsequent Therapy

After First-Line Immunotherapy Progression

Following discontinuation of immune checkpoint inhibitor combinations due to progression or adverse events, tyrosine kinase inhibitors can be considered in selected patients 1. This represents a weak recommendation based on Level 4 evidence.

Isolated Progression on Systemic Therapy

If a patient demonstrates sustained response to systemic therapy but develops isolated site progression, treat that site with local therapy while continuing systemic therapy 1. This "treat-through" approach maintains systemic disease control while addressing focal resistance.

Duration of Immunotherapy in Responders

The consequences of discontinuing immune checkpoint inhibitors in sustained responders remain unknown 1. The decision should be made through shared decision-making, discussing unknown risks and benefits with the patient.

Common Pitfalls to Avoid

1. Do not use prognostic or predictive scores to choose between embolic and systemic therapy—these scores identify patients unlikely to benefit from either, not which therapy to select 1

2. Do not offer SIRT as an alternative to systemic therapy in intermediate-stage patients unfit for TACE/TAE, unless systemic therapy is contraindicated and a lobar approach is possible 1

3. Do not continue TACE beyond one or two consecutive treatments without response—switch to alternative therapies when liver function is preserved 1

4. Do not assume radiographic response alone defines curative-intent candidacy after immunotherapy—technical suitability, oncologic suitability, and liver reserve must all be assessed 5

5. Do not use immunotherapy in post-transplant recurrence due to rejection risk 1

Response Assessment

Use RECIST v1.1 as the primary response assessment method 1. Modified RECIST and iRECIST can serve as secondary assessments where appropriate, but RECIST v1.1 should guide clinical decision-making.